HEALTH PROFESSIONAL · SOURCE READING
Treatment of Metastatic Childhood Soft Tissue Sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Standard treatment options for metastatic childhood soft tissue sarcoma include the following:
Multimodality therapy using chemotherapy, radiation therapy, and surgical resection of pulmonary metastases.
For treatment options, see the individual tumor type sections of the summary.
The prognosis for children with metastatic soft tissue sarcomas is poor.[1-6] In a prospective randomized trial, chemotherapy with vincristine, dactinomycin, doxorubicin, and cyclophosphamide, with or without dacarbazine, led to tumor responses in one-third of patients with unresectable or metastatic disease. However, the estimated 4-year survival rate was poor. Less than one-third of children survived.[6-8]
Targeted (stereotactic body) radiation therapy is an option for sites of metastasis, particularly the lung.[9] Targeted radiation therapy is also an option for local control or sites of metastasis, including the lungs, bones, and brain,[10,11] particularly in patients for whom the morbidity of resection is a concern or whose life expectancy is limited.[9]
In a prospective trial of children with metastatic soft tissue sarcoma, patients were randomly assigned to receive multiagent chemotherapy with or without the addition of bevacizumab.[12] There was no difference in event-free survival or overall survival between the two study arms.
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle